Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.» Read More
Bristol-Myers Squibb Thursday said third-quarter earnings more than doubled on higher drug revenue, including a strong rebound for its Plavix blood-clot preventer, and raised its 2007 profit forecast.
Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.
Eli Lilly said it stopped giving its experimental blood-clot preventer prasugrel to heart patients in two small trials, noting that the dosage of the drug may have to be adjusted for certain types of patients.
The Big Pharma earnings season is in full swing with Pfizer (PFE), Eli Lilly (LLY) and Wyeth (WYE) out Thursday and Merck (MRK) and Schering-Plough (SGP) reporting Monday. What’s the trade as the drug companies deal with their ailing pipelines?
U.S. regulators said warnings about the risk of sudden hearing loss linked to popular drugs for impotence, including Viagra, Cialis and Levitra, would be added to the drugs' labels.
Stocks ended mixed as Bank of America's earnings shortfall was countered by strong tech and healthcare earnings. "In the last few days there is more concern about this bleeding into the fourth quarter, with the Bank of America comments and housing having more of a negative impact on the consumer than maybe we've seen so far," said Alec Young, equity strategist at S&P.
Just months after launching what was hailed as a revolutionary new product, Pfizer is taking it off the market. And it has nothing to do with safety. It has everything to do with sales--or the lack, thereof. The world's biggest drug company only recently started direct-to-consumer advertising for Exubera, but it apparently didn't work.
How's the health of Big Pharma? Not bad, judging from Pfizer, Eli Lilly and Wyeth results. Still, the drug market leaders could use some diet and exercise, here and there ...
Eli Lilly said Thursday third-quarter profit rose on higher sales of newer prescription drugs, including its Cymbalta anti-depressant, and the company raised its 2007 forecast.
Technology has been a big lure in an otherwise fishy stock market this week.
The U.S. Food and Drug Administration said it had reviewed 30 reports of pancreatitis in patients taking Byetta, known generically as exenatide.
This morning on "Squawk Box" and "Squawk on the Street" I reported on a new study showing that a simple blood test might predict whether you will develop Alzheimer's Disease. The report, which appears in the scientific, peer-reviewed journal "Nature Medicine...
By the end of the coming week, the corporate earnings picture will be clear and it may not necessarily be one the stock market likes.
Scott Richter, portfolio manager with Fifth Third Asset Management, oversees the Fifth Third Disciplined Large Cap Value Fund. The fund is up 8 percent year-to-date and 13 percent over the last three years. The strategist offered CNBC viewers and CNBC.com readers a few of his favorite stocks in the health care and biotechnology sector.
The Dow is sitting at a new high and you could argue that the move in the pharmaceuticals sector today is largely market related with Dow components Merck, Pfizer and Johnson & Johnson all trading up. As I write this the biggest dollar gainer in the group is Eli Lilly. But the largest percentage gainer is Schering-Plough.
A couple of days home sick with daytime television as your nursemaid can tell you a lot about the current state of multi-billion dollar pharmaceutical advertising. Yeah, we all know it's ubiquitous, but there are at least a couple of noticeable new players and an older one hitting the airwaves.
Drug developer Eli Lilly said Friday the Food and Drug Administration approved its osteoporosis drug Evista for use in reducing the risk of invasive breast cancer.
For some time now I've been occasionally blogging about the data on a once-a-week version of Byetta that are expected in the fourth quarter sometime. This is a long-acting release (LAR, for short) version of the current twice-a-day injectable drug for diabetes from Lilly and Amylinspacer. Alkermes makes the technology that extends the drug's release.
An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout session. And pretty much the only thing investors and analysts wanted to talk about is Byetta LAR (long-acting release).
Does the thought of raking leaves and covering the patio furniture make you sick? Well, you might be happy to hear that drug maker Eli Lilly is up 10% year to date. But, does your medicine cabinet hold a prescription to profits?